

## Dealdoc

Amendment to co-development and licensing agreement for naproxen and esomeprazole combination for pain

AstraZeneca Pozen

Sep 19 2006

## Amendment to co-development and licensing agreement for naproxen and esomeprazole combination for pain

Companies:

<u>AstraZeneca</u>

Pozen

	Announcement date:	Sep 19 2006
		Co-development and licensing agreement for Vimovo (naproxen and
		esomeprazole combination) for pain
		First amendment to co-development and licensing agreement for
	Poloto di controlato	naproxen and esomeprazole combination for pain
	Related contracts:	Amendment to co-development and licensing agreement for naproxen
		and esomeprazole combination for pain
		Second amendment to co-development and licensing agreement for
		naproxen and esomeprazole combination for pain
		naproxon and cosmoprazoro combination for pain
<ul> <li><u>Details</u></li> </ul>		
• Financials		
• <u>Financials</u>		
• Termsheet		
<ul> <li>Press Release</li> </ul>		
Filing Data		
i mig Data		
<ul> <li>Contract</li> </ul>		
Details		
	Announcement date:	Sep 19 2006
	Start date:	Sep 19 2006
		Bigpharma
	Industry sectors:	Pharmaceutical
		Central Nervous System » Pain
	Therapy areas:	Musculoskeletal » Arthritis » Osteoarthritis
		Musculoskeletal » Arthritis » Rheumatoid arthritis
		Drug delivery
	Technology types:	Small molecules
		Co-development
	Deal components:	Licensing
		Phase III
	Stages of development:	Formulation
	Geographic focus:	Worldwide
	Geograpino locas.	Wondwide
Financials		
i ilialiciais		
Termsheet		
Not available.		
Press Release		
Not available.		
Filing Data		
-9		
Not available.		
i ioi a vallabio.		

## Contract

September 19, 2006

Re: Collaboration and License Agreement dated as of August 1, 2006 by and between POZEN INC. and Astrazeneca AB (the "Collaboration Agreement")

Dear Denise:

This letter sets forth the understanding between POZEN INC. ("POZEN") and Astrazeneca AB ("Astrazeneca") with regard to the matters set forth below and in connection with the Collaboration Agreement. Any capitalized terms not otherwise defined herein shall have the meaning given such term in the Collaboration Agreement. POZEN and Astrazeneca herein are collectively referred to as the Parties.

- 1. In accordance with Section 12.1 of the Collaboration Agreement, the Effective Date of the Collaboration Agreement is September 7, 2006.
- 2. The Parties have attached hereto final versions of Schedule 10.1 and Schedule 10.7, which shall be incorporated by this reference and made part of the Collaboration Agreement.
- 3. The Parties agree that a final schedule of Formulation Development Activities and a Formulation Budget pursuant to Section 6.1.4 of the Collaboration Agreement shall be agreed by the Parties as soon as reasonably practicable but not later than \*\*\*\*\*.
- 4. This letter is being executed pursuant to the terms of Section 15.6 of the Collaboration Agreement and shall be governed by the general terms of Article 15 of the Collaboration Agreement. Except as otherwise expressly provided in this letter, the terms of the Collaboration Agreement shall remain in full force and effect. This letter may be executed in counterparts, each of which when so executed and delivered shall be an original, and all of which together shall constitute one instrument.

**** Portion for which confidential treatment requested.	
this letter reflects your understanding, please countersign in the space provided below and return one original copy to POZEN by facsimi 919) 913-1039.	le at
egards,	
ohn R. Plachetka	
hairman, President and CEO	
GREED:	
STRAZENECA AB (publ)	
y:	
ame: Denise Goode	
itle: Licensing Director	
**** Portion for which confidential treatment requested.	
2 -	
CHEDULE 10.1	
art 10.1.14 - Agreements	
onsultant/Vendor Form of Contract Service Description	
*** **** ****	

\*\*\*\* \*\*\*\* \*\*\*\*

**** *****			
***** *****			
***** *****			
***** *****			
***** *****			
***** *****			
***** *****			
***** ***** *****			
***** ***** *****			
***** *****			
**** *****			
***** ***** *****			
**** *****			
**** *****			
**** *****			
**** *****			
***** *****			
***** Portion for which confidential treatment requested.			
- 3 -			
SCHEDULE 10.7			
POZEN SUBCONTRACTORS			
****			
If AstraZeneca provides POZEN with written notice describing in reasonable detail information that has reasonably and in good faith caused AstraZeneca to believe that it would not be in the best interest of the Product for POZEN to enter into any new subcontract with any of the subcontractors listed above, then POZEN will not, without AstraZeneca's prior written consent (not to be unreasonably withheld) engage such subcontractor in the conduct of Development activities under the Agreement.			
301264 v2/RE			
***** Portion for which confidential treatment requested.			
- 4 -			